Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial (Q40241401)
Jump to navigation
Jump to search
scientific article published on 14 November 2015
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial |
scientific article published on 14 November 2015 |
Statements
1 reference
Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial (English)
1 reference
Elisabeth Steinhagen-Thiessen
1 reference
Michel Farnier
1 reference
Peter Jones
1 reference
Randall Severance
1 reference
Yunling Du
1 reference
Corinne Hanotin
1 reference
Stephen Donahue
1 reference
14 November 2015
1 reference
1 reference
Identifiers
1 reference